Prime Editing Gene Therapy Just Cured a Teenager’s Rare Disease — Here’s Why It Changes Everything

A 19-year-old Canadian spent his entire childhood on daily medication just to stay alive. Then private science — not a government program — rewrote two letters of his DNA and set him free.

For fourteen years, Ty Sperle woke up every morning and took a fistful of pills. Antibiotics. Antifungals. Not because he was sick that week — but because without them, a routine infection could kill him. Diagnosed at age five with chronic granulomatous disease (CGD), a rare inherited immune disorder, Ty’s body simply could not fight bacteria and fungi the way a healthy immune system does. Doctors spent years searching for a bone marrow donor match that never came. Medicine, by every conventional measure, had run out of options.

Then, in the summer of 2025, a biotechnology company inserted a gene-editing tool into Ty’s own blood stem cells, corrected a two-letter spelling mistake in his DNA, and gave him back his life. Today, Ty Sperle takes zero daily medication. He is a student at UBC Okanagan. He is, by every medical measure, cured. And he is the first human being on earth to be cured using a technology called prime editing.

What Prime Editing Is — and Why It’s Different from CRISPR

Most people have heard of CRISPR, the gene-editing technology that made headlines a decade ago as a potential cure for everything. CRISPR works, but it has a significant flaw: it cuts both strands of the DNA double helix simultaneously, which creates off-target edits — unintended changes elsewhere in the genome that can cause serious problems, including potentially triggering cancer.

Prime editing, invented in 2019 by Dr. David Liu at the Broad Institute, takes a fundamentally different approach. Instead of cutting, it searches. It finds the exact genetic mutation — in Ty’s case, a two-letter deletion in the NCF1 gene — and rewrites only those letters, like a molecular find-and-replace. No double-strand break. No genomic scissors left unattended. The result is a far more precise, far safer edit.

This is not incremental progress. This is a generational leap in what medicine can do.

The Science Behind Ty’s Cure

The treatment, called PM359 and developed by US-based Prime Medicine, is what scientists call an autologous therapy — meaning it uses the patient’s own cells. Doctors drew Ty’s blood stem cells, enriched them in a lab, then used prime editing to correct the NCF1 mutation. Those corrected cells were infused back into Ty’s body. His immune system rebuilt itself around them.

The results, published in the New England Journal of Medicine in December 2025, are striking. NADPH oxidase activity — the immune function that CGD destroys — was restored within one month and remained durable at six months of follow-up. A second participant in the same Phase I/II clinical trial showed the same result at four months.

Adverse events were linked to busulfan, the conditioning chemotherapy used to prepare Ty’s body for the new cells — not to the prime editing itself. That distinction matters enormously for future patients and for regulatory confidence in the technology.

Private Innovation Did What Government Medicine Could Not

Here is a fact worth sitting with: Ty Sperle was diagnosed in 2011. He waited fourteen years for a cure. Government-supported bone marrow donor registries never found him a match. The standard treatment for CGD requires a genetic donor match that many patients never find. For those patients, traditional medicine simply closes the door.

What opened it again was not a federal program. It was a private biotechnology company — Prime Medicine — working in collaboration with research hospitals in Canada and the United States. The trial was run out of CHU Sainte-Justine in Montreal. The science originated at the Broad Institute in Cambridge, Massachusetts. The funding came from private investors and targeted philanthropic sources, including the Cystic Fibrosis Foundation, which committed up to $24 million in additional investment toward Prime Medicine’s pipeline.

When the government-run system had nothing left to offer, private science stepped in and rewrote the rules.

This is what fiscal conservatives and free-market advocates have argued for decades: that innovation accelerates when researchers are freed from bureaucratic constraint, when capital flows to ideas based on merit, and when companies are incentivized to solve hard problems. The cure for Ty Sperle’s disease did not emerge from a federal grant committee. It emerged from competitive, mission-driven science backed by private investment.

The FDA Question: Will Government Get Out of the Way?

Now the real test begins. Prime Medicine is pursuing FDA approval for PM359 — based on data from just two patients. That’s not a typo. Two patients.

Under traditional FDA frameworks, that number would be dismissed. But rare diseases demand a different standard. CGD affects roughly one in 200,000 children. The total patient pool is inherently small. Requiring thousands of trial participants before approval isn’t rigorous — it’s a death sentence for rare disease patients who have no other options.

The FDA has signaled it wants to be more flexible on rare disease approvals. Prime Medicine’s Biologics License Application will test exactly how serious that commitment is. The agency has recently rejected some gene therapies for neurological diseases, so there is no guarantee. But the data for PM359 is clean, the safety profile is strong, and the mechanism of action is well-understood.

Getting this right matters for thousands of patients waiting in the wings. There are hundreds of rare genetic diseases caused by single-gene mutations — the exact type of targeted correction prime editing is designed to make. The regulatory precedent set here will either open the door for a wave of cures, or slam it shut with red tape.

What Critics Get Wrong

Some voices will argue that cures like this one prove we need more government funding, more public research infrastructure, more centralized control over biotechnology development. That argument collapses under scrutiny.

The core science of prime editing did originate at the Broad Institute, which receives some public funding through the NIH. Nobody disputes that basic research funding has value. But the translation from laboratory discovery to clinical treatment — the hard part, the expensive part, the risky part — was done by a private company willing to bet its existence on an unproven technology.

Government agencies don’t take those bets. They are structurally designed to avoid failure, which means they are also structurally designed to avoid the kinds of bold, high-risk innovation that produce breakthroughs. The lesson isn’t “fund more government science.” It’s “create the conditions — low regulatory barriers, strong IP protections, and accessible private capital — that let companies like Prime Medicine do what they do.”

Parents of children with rare diseases don’t need more bureaucracy. They need more Ty Sperle stories.

What This Means for the 1 in 3

At BC Children’s Hospital, where Ty was treated for over a decade, roughly one in every three children admitted has a rare disease. One in three. That is not a footnote statistic — it is a staggering measure of how many families are living with conditions that conventional medicine cannot fix.

Prime editing’s “search and replace” mechanism is, in principle, adaptable. The same platform that corrected two letters in Ty’s NCF1 gene can be redirected to target different mutations in different genes. Prime Medicine already has programs in development for cystic fibrosis and other conditions. The infrastructure being built to cure CGD is the same infrastructure that could cure dozens of other diseases.

For the first time in history, “your child has a rare genetic disease and there’s no cure” does not have to be the end of the story.

Key Takeaway

A 19-year-old who spent his childhood surviving on daily medication is now medication-free, thanks to private biomedical innovation, precision gene editing, and a regulatory environment willing to be flexible enough to let it happen. The technology works. The data is published. The FDA application is filed. The only thing that can slow this down now is government getting in its own way.

Stay Informed. Share This Story.

Medical breakthroughs like Ty Sperle’s cure don’t happen by accident — they happen because private innovators are given the freedom and the capital to pursue them. If you believe in the power of innovation over bureaucracy, and in the right of every family to access the best that science can offer, share this article and keep the conversation going. Independent journalism depends on readers who care enough to pass it along.

Sources: New England Journal of Medicine (PMID 41358590, December 2025); BC Children’s Hospital Research Institute, February 27, 2026; STAT News, March 3, 2026; Prime Medicine investor communications; Cystic Fibrosis Foundation, July 2025.